Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discount will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Most Popular in Pharmaceuticals
Eli Lilly and Company will invest $60 million in cash and stock in Sitryx, a British biotech firm developing immuno-oncology and immuno-inflammation drugs that work by regulating cell metabolism. Under the pact, Lilly gets the right to develop four Sitryx therapies, including its two lead projects. Sitryx launched in 2018 with $30 million in funding from GlaxoSmithKline and others.
This article has been sent to the following recipient: